🚀 VC round data is live in beta, check it out!
NRX Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for NRX Pharmaceuticals and similar public comparables like MediciNova, Paradigm Biopharma, Rani Therapeutics, Fractyl Health and more.
NRX Pharmaceuticals Overview
About NRX Pharmaceuticals
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Founded
2017
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$66M
NRX Pharmaceuticals Financials
NRX Pharmaceuticals reported last 12-month revenue of $38M and negative EBITDA of ($7M).
In the same LTM period, NRX Pharmaceuticals generated $34M in gross profit, ($7M) in EBITDA losses, and had net loss of ($2M).
Revenue (LTM)
NRX Pharmaceuticals P&L
In the most recent fiscal year, NRX Pharmaceuticals reported revenue of $1M and EBITDA of ($14M).
NRX Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $38M | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | $34M | XXX | $720K | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | ($7M) | XXX | ($14M) | XXX | XXX | XXX |
| EBITDA Margin | (19%) | XXX | (1118%) | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | (1324%) | XXX | XXX | XXX |
| Net Profit | ($2M) | XXX | ($29M) | XXX | XXX | XXX |
| Net Margin | (5%) | XXX | (2336%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NRX Pharmaceuticals Stock Performance
NRX Pharmaceuticals has current market cap of $73M, and enterprise value of $66M.
Market Cap Evolution
NRX Pharmaceuticals' stock price is $2.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $66M | $73M | -1.8% | XXX | XXX | XXX | $-0.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNRX Pharmaceuticals Valuation Multiples
NRX Pharmaceuticals trades at 1.8x EV/Revenue multiple, and (9.2x) EV/EBITDA.
EV / Revenue (LTM)
NRX Pharmaceuticals Financial Valuation Multiples
As of April 11, 2026, NRX Pharmaceuticals has market cap of $73M and EV of $66M.
Equity research analysts estimate NRX Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NRX Pharmaceuticals has a P/E ratio of (35.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $73M | XXX | $73M | XXX | XXX | XXX |
| EV (current) | $66M | XXX | $66M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 54.1x | XXX | XXX | XXX |
| EV/EBITDA | (9.2x) | XXX | (4.8x) | XXX | XXX | XXX |
| EV/EBIT | 8.5x | XXX | (4.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | 92.0x | XXX | XXX | XXX |
| P/E | (35.3x) | XXX | (2.6x) | XXX | XXX | XXX |
| EV/FCF | (9.3x) | XXX | (4.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NRX Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NRX Pharmaceuticals Margins & Growth Rates
NRX Pharmaceuticals' revenue in the last 12 month grew by 549%.
NRX Pharmaceuticals' rule of 40 is 10801% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NRX Pharmaceuticals' rule of X is 26993% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
NRX Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 549% | XXX | 10794% | XXX | XXX | XXX |
| EBITDA Margin | (19%) | XXX | (1118%) | XXX | XXX | XXX |
| EBITDA Growth | (493%) | XXX | (171%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 10801% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 26993% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 62% | XXX | 1066% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | 308% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1383% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NRX Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| MediciNova | XXX | XXX | XXX | XXX | XXX | XXX |
| Paradigm Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Rani Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fractyl Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Q32 Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NRX Pharmaceuticals M&A Activity
NRX Pharmaceuticals acquired XXX companies to date.
Last acquisition by NRX Pharmaceuticals was on XXXXXXXX, XXXXX. NRX Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NRX Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNRX Pharmaceuticals Investment Activity
NRX Pharmaceuticals invested in XXX companies to date.
NRX Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. NRX Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NRX Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NRX Pharmaceuticals
| When was NRX Pharmaceuticals founded? | NRX Pharmaceuticals was founded in 2017. |
| Where is NRX Pharmaceuticals headquartered? | NRX Pharmaceuticals is headquartered in United States. |
| Who is the CEO of NRX Pharmaceuticals? | NRX Pharmaceuticals' CEO is Jonathan C. Javitt. |
| Is NRX Pharmaceuticals publicly listed? | Yes, NRX Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of NRX Pharmaceuticals? | NRX Pharmaceuticals trades under NRXP ticker. |
| When did NRX Pharmaceuticals go public? | NRX Pharmaceuticals went public in 2021. |
| Who are competitors of NRX Pharmaceuticals? | NRX Pharmaceuticals main competitors are MediciNova, Paradigm Biopharma, Rani Therapeutics, Fractyl Health. |
| What is the current market cap of NRX Pharmaceuticals? | NRX Pharmaceuticals' current market cap is $73M. |
| What is the current revenue of NRX Pharmaceuticals? | NRX Pharmaceuticals' last 12 months revenue is $38M. |
| What is the current revenue growth of NRX Pharmaceuticals? | NRX Pharmaceuticals revenue growth (NTM/LTM) is 549%. |
| What is the current EV/Revenue multiple of NRX Pharmaceuticals? | Current revenue multiple of NRX Pharmaceuticals is 1.8x. |
| Is NRX Pharmaceuticals profitable? | No, NRX Pharmaceuticals is not profitable. |
| What is the current EBITDA of NRX Pharmaceuticals? | NRX Pharmaceuticals has negative EBITDA and is not profitable. |
| What is NRX Pharmaceuticals' EBITDA margin? | NRX Pharmaceuticals' last 12 months EBITDA margin is (19%). |
| What is the current EV/EBITDA multiple of NRX Pharmaceuticals? | Current EBITDA multiple of NRX Pharmaceuticals is (9.2x). |
| What is the current FCF of NRX Pharmaceuticals? | NRX Pharmaceuticals' last 12 months FCF is ($7M). |
| What is NRX Pharmaceuticals' FCF margin? | NRX Pharmaceuticals' last 12 months FCF margin is (19%). |
| What is the current EV/FCF multiple of NRX Pharmaceuticals? | Current FCF multiple of NRX Pharmaceuticals is (9.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.